The latest price target for NeoGenomics (NASDAQ:NEO) was reported by Stephens & Co. on July 30, 2024. The analyst firm set a price target for $19.00 expecting NEO to rise to within 12 months (a possible 17.57% upside). 20 analyst firms have reported ratings in the last year.

The latest analyst rating for NeoGenomics (NASDAQ:NEO) was provided by Stephens & Co., and NeoGenomics reiterated their overweight rating.

The last upgrade for NeoGenomics Inc happened on August 21, 2023 when Stephens & Co. raised their price target to $18. Stephens & Co. previously had an equal-weight for NeoGenomics Inc.

The last downgrade for NeoGenomics Inc happened on May 16, 2023 when Raymond James changed their price target from N/A to N/A for NeoGenomics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NeoGenomics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NeoGenomics was filed on July 30, 2024 so you should expect the next rating to be made available sometime around July 30, 2025.

While ratings are subjective and will change, the latest NeoGenomics (NEO) rating was a reiterated with a price target of $19.00 to $19.00. The current price NeoGenomics (NEO) is trading at is $16.16, which is out of the analyst’s predicted range.